Floatz logo

URSODEOXYCHOLIC ACID

Nonalcoholic Fatty Liver Disease (NAFLD)

Phenomen PharmaSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Nonalcoholic Fatty Liver Disease (NAFLD) cohort.

Asset / SponsorPhaseRating
A THERAPEUTIC PEGYLATED FIBROBLAST GROWTH FACTOR 21 AGONIST/MIMETIC WHICH RESTORES LEPTIN RESPONSIVENESS
Bristol-Myers Squibb
Phase 2BB
LEVAMLODIPINE
Nanfang Hospital, Southern Medical University
Phase 4BB
AMLODIPINE
Nanfang Hospital, Southern Medical University
Phase 4BB
Micardis®
Nanfang Hospital, Southern Medical University
Phase 4B
Dr Cysteamine Bitartrate
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2/3B

View all 11 →

Same molecule, other indications

URSODEOXYCHOLIC ACID is also rated in:

primary biliary cholangitisDormant
A
Indicative ·
82 / 100
View asset →
Nonalcoholic Steatohepatitis (NASH)Dormant
BBB
Indicative ·
74 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →